--- title: 'Senior Director, Pipeline Commercial Strategy at Iovance Biotherapeutics' canonical: 'https://feeny.ai/job/senior-director-pipeline-commercial-strategy-iovance-biotherapeutics-remote-925a5g5qa15d' type: 'job' last_seen: '2026-10-29' --- # Senior Director, Pipeline Commercial Strategy at Iovance Biotherapeutics - **Company:** Iovance Biotherapeutics - **Location:** Remote - **Compensation:** $270k–$290k - **Work type:** remote - **Posted:** 2026-10-23 - **Last confirmed live:** 2026-10-29 - **Apply:** https://job-boards.greenhouse.io/iovancebiotherapeutics/jobs/5461806008 ## Job description About Iovance Biotherapeutics, Inc. [Iovance Biotherapeutics](https://www.iovance.com/), Inc.  is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The [Iovance TIL platform](https://www.iovance.com/our-science/til-platform/) spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit [www.iovance.com](http://www.iovance.com/). Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on [www.iovance.com](http://www.iovance.com/). ## Overview The Sr. Director, Pipeline Commercial Strategy will own the commercial assessment of Iovance's pipeline assets, including market sizing, target product profiles and competitive analysis. This role brings deep commercial domain expertise to quantify market opportunities, shape portfolio and indication strategy, and ensure disciplined execution of priority workstreams from early, upstream pipeline development. This commercial subject matter expert will proactively identify what needs to be done, define the path forward, and drive the organization to execute. Essential Functions and Responsibilities - Senior commercial strategy role owning the commercial assessment of pipeline assets and indication expansions including market sizing and addressable market analysis, target product profiles (TPPs), competitive analysis, and representing reimbursement market analysis from early development through launch - Defines and drives actionable commercial strategies, workplans, timelines, and readiness deliverables grounded in deep knowledge of oncology markets, treatment paradigms, and cell therapy commercialization - Represents Commercial in established enterprise forums such as PDT and GDT, operating as the strategic integrator who drives alignment through expertise New Product Planning & Portfolio Strategy - Build market sizing and addressable market analyses by tumor type, line of therapy, and geography, using epidemiology, treatment-flow, and claims data to quantify the commercial opportunity - Develop and maintain commercially grounded target product profiles (TPPs) for pipeline assets, defining the efficacy, safety, dosing, and differentiation thresholds needed to compete in each target indication - Own competitive analysis and scenario planning for pipeline indications, tracking competitor programs, data readouts, and approvals, modeling competitive entry, label variation, treatment landscape shifts, and outpatient usage opportunities, and defining the differentiation strategy for Iovance assets - Drive portfolio prioritization, forecasting, and commercial recommendations to inform Go/No-Go decisions for registrational trials - Lead early commercial assessments for pipeline assets, indication expansions, in-licensing opportunities, acquisitions, and business development evaluations, applying deep market knowledge to shape investment decisions - Provide commercial input on tumor target, indication, and launch market selection, including signal-finding studies and investigator-sponsored trials (ISTs) that support future registrational trials - Partner with Clinical Development and project teams to influence clinical milestones, trial design assumptions, accelerated or regular approval pathways, and regional commercialization considerations based on commercial viability and market dynamics - Own launch trackers, readiness scorecards, risk registers, and milestone dashboards as strategic tools using them to anticipate issues and drive proactive decision-making, not simply report status - Must adhere to Iovance Biotherapeutics’ core values, policies, procedures, and business ethics. - Perform miscellaneous duties as assigned. Required Education, Skills, and Knowledge - Bachelor's degree required; advanced degree such as MBA, MPH, PharmD, PhD, or relevant graduate degree preferred - Typically 10+ years (Sr. Director/Director) of biopharmaceutical, biotech, oncology, cell therapy, specialty medicine, commercial strategy, launch planning, brand strategy, market access, consulting, or related experience - Hands-on experience building market sizing and addressable market models, target product profiles, competitive assessments, and reimbursement or payer analyses for oncology or cell therapy assets - Deep commercial domain expertise, this role requires someone who has personally shaped commercial strategy and made market-facing decisions, not solely managed timelines or coordinated workstreams - Demonstrated ability to lead complex cross-functional initiatives, develop strategic recommendations grounded in data, and influence senior stakeholders through expertise and credibility - Track record of leading product launches, new product planning, commercial assessments, forecasting, portfolio strategy, or launch readiness, as a strategic driver, not a project manager - Strong executive presence, written communication, analytical thinking, and ability to influence without authority in a matrixed environment Physical Demands and Activities Required The physical demands described here represent those an employee may encounter while performing the essential functions of this job. Reasonable accommodation may be provided to enable individuals to perform these functions. - Ability to remain in a stationary position for extended periods - Ability to move about within an office or remote workspace and exert up to 10 pounds of force occasionally - Visual acuity sufficient for preparing and analyzing data, viewing computer screens, and extensive reading - Repetitive motion involving wrists, hands, and/or fingers - Ability to communicate effectively to exchange information - Ability to engage in analytical, conceptual, and problem‑solving activities in a dynamic business environment Mental: Clear and conceptual thinking ability; excellent judgment, troubleshooting, problem-solving, analysis, and discretion; ability to handle work-related stress; ability to handle multiple priorities simultaneously with a sense of urgency; and ability to meet deadlines Work Environment This job operates in a professional or remote office environment and requires operating standard office equipment and keyboards. #li-remote The annual base salary we reasonably expect to pay is listed. Individual pay decisions depend on various factors, such as primary work location, complexity and responsibility of the role, job duties/requirements, and relevant education, experience and skills. Pay Transparency $270,000—$290,000 USD The statements contained in this document are intended to describe the general nature and level of work being performed by a colleague assigned to this description. They are not intended to constitute a comprehensive list of functions, duties, or local variances. Management retains the discretion to add or to change the duties of the position at any time. Iovance is committed to cultivating and offering a diverse and inclusive work environment. As an equal-opportunity employer, our employees and applicants will be considered without regard to an individual’s race, color, religion, sex, pregnancy, national origin, age, physical and mental disability, marital status, sexual orientation, gender identity, gender expression, genetic information, military and veteran status, and any other characteristic protected by applicable law. If you need assistance or accommodation to apply to one of our opportunities, please contact careers@iovance.com. By voluntarily providing information and clicking “Submit Application”, you explicitly consent to the collection and use of your personal information for the purposes described above and in our [Candidate Privacy Notice](https://www.iovance.com/privacy-policy/). ## About Iovance Biotherapeutics ## Company Overview - **One-liner**: Iovance Biotherapeutics is pioneering tumor infiltrating lymphocyte (TIL) cell therapies to develop personalized, one-time treatments for solid tumor cancers. - **Entity Type**: Public (NASDAQ: IOVA) - **Headquarters**: San Carlos, California, USA - **Founded**: 2007 (originally named Lion Biotechnologies, renamed Iovance Biotherapeutics in 2017) - **Founders**: Not publicly available (the company was formed through a merger and rebranding) ## Core Business - **Primary industry**: Biotechnology — Cell Therapy (Immuno-Oncology) - **Target customers**: B2B / B2G — Healthcare providers, clinical trial sites, and ultimately patients with advanced solid tumors (melanoma, non-small cell lung cancer, endometrial cancer, etc.) - **Mission or purpose statement**: To be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer, harnessing the immune system to recognize and attack diverse cancer cells. ## Products & Services - **Lifileucel (IOV-009)**: A one-time, personalized TIL therapy for advanced melanoma. It is the first approved TIL therapy for a solid tumor (FDA approved in early 2024 under the brand name Amtagvi). - **IOV-LUN-202**: An investigational TIL therapy for advanced non-small cell lung cancer (NSCLC) currently in Phase 2 clinical trials. - **IOV-END-201**: An investigational TIL therapy for advanced endometrial cancer currently in Phase 2 clinical trials. - **IOV-4001**: A next-generation, gene-edited TIL therapy (using TALEN technology to inactivate PD-1 expression) for solid tumors, currently in preclinical/early clinical development. - **IOV-3001**: An engineered IL-2 therapy (licensed from Novartis) designed to support TIL therapy efficacy, currently in preclinical development. - **Cell Therapy Manufacturing (iCTC)**: The company operates a 136,000-square-foot, state-of-the-art Cell Therapy Center in Philadelphia, PA, for proprietary GMP manufacturing of TIL therapies. ## Market Standing - **Valuation/Market Cap**: As of early 2026, market capitalization is approximately $2.5–3.0 billion (fluctuates with FDA news and clinical data). Check current price on NASDAQ: IOVA. - **Key Metric (Revenue)**: Iovance generated its first commercial revenue from Lifileucel/Amtagvi in 2024. Annual revenue for 2025 was approximately $180–220 million (estimate based on analyst reports; exact figure not yet fully disclosed). The company is not yet profitable. - **Key Metric (Funding)**: As a public company, Iovance has raised over $1.5 billion through public offerings and debt financings. Notable recent raise: a public offering in 2022 and subsequent at-the-market offerings. - **Notable Investors/Partners**: - Novartis (license partner for IOV-3001) - Major institutional investors (e.g., BlackRock, Vanguard, and several healthcare-focused funds) - Collaborations with major cancer centers for clinical trials (e.g., MD Anderson, Memorial Sloan Kettering, etc.) - **Growth Signals**: - FDA approval of Lifileucel (Amtagvi) in early 2024 — a landmark first-in-class approval for TIL therapy in solid tumors. - Rapid commercial launch and expansion of treatment centers across the U.S. - Multiple ongoing Phase 2/3 trials in large indications (NSCLC, endometrial cancer, frontline melanoma). - Investment in next-generation gene-edited TIL (IOV-4001) and engineered IL-2 (IOV-3001) to improve efficacy and expand addressable patient populations. ## Competitive Advantages - **First-to-market TIL therapy**: Iovance is the only company with an FDA-approved TIL therapy for a solid tumor (Amtagvi for melanoma), giving it a significant head start in manufacturing, commercial infrastructure, and physician education. - **Proprietary manufacturing platform**: The in-house iCTC facility in Philadelphia enables scalable, standardized GMP production of personalized TIL therapies, a major barrier to entry for competitors. - **Broad solid tumor pipeline**: Unlike CAR-T therapies (primarily effective in blood cancers), TIL therapy has shown promise across multiple solid tumor types, providing a large addressable market. - **Polyclonal T cell approach**: The therapy targets a broad range of neoantigens unique to each patient’s tumor, potentially reducing the risk of immune escape compared to single-target therapies. ## Strategic Focus - **Commercial expansion**: Scaling up the launch of Amtagvi for advanced melanoma and expanding treatment center network globally. - **Pipeline acceleration**: Advancing pivotal trials in NSCLC (IOV-LUN-202) and endometrial cancer (IOV-END-201) to secure additional FDA approvals. - **Next-generation innovation**: Developing gene-edited TIL (IOV-4001) to enhance persistence and efficacy, and engineered IL-2 (IOV-3001) to improve the TIL therapy cycle. - **Manufacturing optimization**: Continuing to improve manufacturing efficiency and turnaround time at the iCTC facility to support growing demand and reduce costs. ## Why Work Here - **Mission-driven culture**: The company is deeply patient-centric, with a clear focus on delivering transformative therapies to cancer patients. Employees often cite the meaningful impact of their work as a key motivator. - **Values**: Integrity, agility, innovation, collaboration, and excellence are core to the company’s operating philosophy. The culture emphasizes transparency, teamwork, and high ethical standards. - **Diversity, Equity, and Inclusion**: Iovance has a stated commitment to DEI, recognizing that internal diversity is critical to serving diverse patient populations and driving innovation. - **Remote/Hybrid policy**: Many roles (especially in clinical, medical affairs, marketing, and commercial functions) are remote or hybrid. Laboratory and manufacturing roles are based on-site in Philadelphia, PA (iCTC) or San Carlos, CA (HQ). - **Benefits**: Competitive salaries, annual cash bonuses, long-term incentives (stock options/RSUs), 401(k) with match, Employee Stock Purchase Plan, comprehensive medical/dental/vision (low employee cost), Health Savings Account contributions, paid parental leave, tuition assistance, wellness program (gym discounts), and professional development opportunities. - **Work environment**: Agile and fast-paced, typical of a biotech company at a critical growth stage. The company values data-driven decision-making and encourages employees to bring their best efforts every day. ## Sources 1. [iovance.com](https://www.iovance.com/) 2. [iovance.com - About Us](https://www.iovance.com/about-iovance-biotherapeutics/) 3. [iovance.com - Culture](https://www.iovance.com/culture/) 4. [job-boards.greenhouse.io](http://job-boards.greenhouse.io/iovancebiotherapeutics) ## Other roles at Iovance Biotherapeutics - [Manager, US Commercial Analytics](https://feeny.ai/job/manager-us-commercial-analytics-iovance-biotherapeutics-remote-pp175wb1c3rg) - [Scientific Director, Medical Affairs](https://feeny.ai/job/scientific-director-medical-affairs-iovance-biotherapeutics-remote-hw991kwkzz0n) - [Associate Director, Clinical Operations](https://feeny.ai/job/associate-director-clinical-operations-iovance-biotherapeutics-remote-x88j1h7q322y) - [Senior Director, Program Team Lead](https://feeny.ai/job/senior-director-program-team-lead-iovance-biotherapeutics-remote-kyypj1s0kgtv) - [Director, U.S Customer Engagement, Strategic Alliances and Advocacy](https://feeny.ai/job/director-u-s-customer-engagement-strategic-alliances-and-advocacy-iovance-qt2mm7vmxfdf) - [Clinical Trial Manager](https://feeny.ai/job/clinical-trial-manager-iovance-biotherapeutics-remote-gn64jtz5q07s) - [Computer Systems Validation Analyst II](https://feeny.ai/job/computer-systems-validation-analyst-ii-iovance-biotherapeutics-remote-4y2b855y8stg) - [Cell Therapy Account Management - North Central ( Preferred location Nebraska)](https://feeny.ai/job/cell-therapy-account-management-north-central-preferred-location-nebraska-jwja6gmgb87q) — Nebraska North Dakota South Dakota and, IA - [Associate Director, Omnichannel Marketing](https://feeny.ai/job/associate-director-omnichannel-marketing-iovance-biotherapeutics-remote-cj02etnvh9s0) - [Senior Director, Authorized Treatment Center (ATC) Cell Therapy Operations](https://feeny.ai/job/senior-director-authorized-treatment-center-atc-cell-therapy-operations-iovance-m8eq9271825v)